Fierce Pharma
MARCH 20, 2024
Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. Sales came to 1.5 billion euros ($1.6 billion) for the fourth quarter and 3.8 billion euros ($4.1 billion) for 2023, coming up short of expectations.
MedCity News
MARCH 20, 2024
The regulatory environment and workforce shortages are plaguing the pharmacy industry, one Walgreens exec shared at the Abarca Forward conference on Tuesday.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 20, 2024
After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy (MLD) in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have | After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too.
MedCity News
MARCH 20, 2024
How targeted outreach and heightened engagement can help companies achieve better outcomes
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MARCH 20, 2024
As two of the world’s largest pharmaceutical companies, Johnson & Johnson and Pfizer have long been rivals in various therapeutic areas. | The company is accusing former employee Andrew Brackbill of downloading thousands of confidential strategy-related files before leaving for rival Pfizer.
MedCity News
MARCH 20, 2024
The “vast majority” of provider-sponsored health plans are unprofitable, Flare Capital Partners Principal Parth Desai pointed out during a recent interview. He said most of these plans aren’t able to cover the large number of lives required to ensure a viable risk pool and maintain a healthy operating margin.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 20, 2024
Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
Fierce Pharma
MARCH 20, 2024
Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. | Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after its Opdivo monotherapy setback five years ago and a subsequent market withdrawal.
pharmaphorum
MARCH 20, 2024
Vicore gets FDA breakthrough status for Almee, a cognitive behavioural therapy (CBT) digital health therapy used to support people with pulmonary fibrosis
Fierce Pharma
MARCH 20, 2024
Early this month at an investor event, Bayer CEO Bill Anderson—the agent for reform of the troubled company—declared that employees “are ready for change. They’re saying bring it on.” | Early this month at an investor event, Bayer CEO Bill Anderson declared that employees “are ready for change." On Wednesday, Anderson answered the call with changes to the company’s leadership.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTimes
MARCH 20, 2024
Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease
pharmaphorum
MARCH 20, 2024
Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.
Pharmaceutical Technology
MARCH 20, 2024
Johnson & Johnson has received approval from the FDA for EDURANT PED to treat human immunodeficiency virus-1 (HIV-1) in children.
European Pharmaceutical Review
MARCH 20, 2024
The US Food and Drug Administration (FDA) has approved gene therapy Lenmeldy (atidarsagene autotemcel) as the first treatment for children with early-onset metachromatic leukodystrophy (MLD). Following a patient receiving chemotherapy, the autologous hematopoietic stem cell-based gene therapy is administered as a personalised, one-time, single-dose infusion.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
MARCH 20, 2024
Swiss CDMO Lonza pays $1.2bn for Roche's biologics manufacturing facility in Vacaville, US, safeguarding around 750 jobs.
European Pharmaceutical Review
MARCH 20, 2024
Lonza has agreed to acquire one of the world’s largest biologics manufacturing sites (by volume), for a total of $1.2 billion from Roche. The acquisition of the manufacturing facility will significantly increase Lonza’s capacity of the manufacture of large-scale biologics, to meet demand for commercial mammalian contract manufacturing. At present, the Genentech Vacaville facility in the US has a total bioreactor capacity of around 330,000 litres.
pharmaphorum
MARCH 20, 2024
EU pharma legislation gets closer to fruition as European Parliament's ENVI committee votes in favour of amendments, but industry remains concerned
Pharmaceutical Commerce
MARCH 20, 2024
Presentation offers insight on this aforementioned model that assists retail and specialty-lite brands.
pharmaphorum
MARCH 20, 2024
A highly anticipated phase 3 trial of a new tuberculosis vaccine developed by GSK has started in Africa, funded by the Gates MRI and Wellcome.
European Pharmaceutical Review
MARCH 20, 2024
According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 million by 2028. The market is growing at a CAGR of 10.16 percent between 2022-2028, the research found. Factors shaping the market partnerships and collaborations “promise huge demand and growth opportunities for small and medium-sized firms to enter the [European LIMS] market” With pharmaceutical and biotechnological industries making large R&D investments, the
pharmaphorum
MARCH 20, 2024
Takeda’s Iclusig is first targeted therapy approved by the FDA for use alongside chemo as a first-line therapy for acute lymphoblastic leukaemia
PharmaTimes
MARCH 20, 2024
In 2021, neurological conditions, including Alzheimer's disease, affected approximately 3.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
MARCH 20, 2024
The study represents a new era of research into mushrooms as a resource for pharmaceutical development.
Clarivate
MARCH 20, 2024
Discover pivotal insights shaping the landscape of U.K. research shared at the second Research Professional News Live summit. From discussions on REF2029 to the imperatives of fostering diversity, innovation and research integrity, we explored the future of research amidst financial challenges and evolving policies. On March 14, the Research Professional News Live summit brought together a stellar group of speakers, panelists and delegates including keynotes from Professor Dame Jessica Corner, E
European Pharmaceutical Review
MARCH 20, 2024
Single-use filtration systems can help streamline processes and enhance efficiency of biopharma production. In this practical guide readers will embark on a journey through pre-filtration and sterile filtration stages, gaining insight into diverse membrane technologies. Download this ebook to: Uncover how pore size and membrane material can be used to tailor filtration processes Learn how to optimise flow rates to balance efficiency and quality Discover how single-use filtration systems can boos
Pharmaceutical Technology
MARCH 20, 2024
The US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP).
Pharmacy Times
MARCH 20, 2024
Regardless, hygiene practices and prevention measures for SARS-CoV-2 should be strongly practiced to prevent all respiratory viruses.
Quantified
MARCH 20, 2024
The internet is full of statistics that demonstrate how vital sales training is. Whether you’re measuring the productivity of each agent, the total ROI of training initiatives, or the percentage increase of closed-won deals, training makes a sizeable difference. The trick is identifying which training methods are contributing to increases and, whenever possible, which training exercises contribute the most to sales success.
Pharmacy Times
MARCH 20, 2024
Legal issues surfaced once again with the COVID-19 pandemic
PharmaTech
MARCH 20, 2024
Dr. Luca Mantilli, an R&D chemist at Valsynthese, shares his insights into the company’s journey with phosgene, an exceptionally versatile reagent that offers various synthetic possibilities.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
336 
Let's personalize your content